145 related articles for article (PubMed ID: 36308382)
21. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
22. Combined genetic influence of the nicotinic receptor gene cluster CHRNA5/A3/B4 on nicotine dependence.
Lee SH; Ahn WY; Seweryn M; Sadee W
BMC Genomics; 2018 Nov; 19(1):826. PubMed ID: 30453884
[TBL] [Abstract][Full Text] [Related]
23. [ROS1-Translocations in Non-Small Cell Lung Cancer].
Warth A; Weichert W; Reck M; Reinmuth N
Pneumologie; 2015 Aug; 69(8):477-82. PubMed ID: 26258422
[TBL] [Abstract][Full Text] [Related]
24. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.
Scheffler M; Schultheis A; Teixido C; Michels S; Morales-Espinosa D; Viteri S; Hartmann W; Merkelbach-Bruse S; Fischer R; Schildhaus HU; Fassunke J; Sebastian M; Serke M; Kaminsky B; Randerath W; Gerigk U; Ko YD; Krüger S; Schnell R; Rothe A; Kropf-Sanchen C; Heukamp L; Rosell R; Büttner R; Wolf J
Oncotarget; 2015 Apr; 6(12):10577-85. PubMed ID: 25868855
[TBL] [Abstract][Full Text] [Related]
25. Single Nucleotide Polymorphism rs6942067 Is a Risk Factor in Young and in Non-Smoking Patients with HPV Negative Head and Neck Squamous Cell Carcinoma.
Cardin GB; Bernard M; Bahig H; Nguyen-Tan PF; Ballivy O; Filion E; Soulieres D; Philouze P; Ayad T; Guertin L; Bissada E; Rodier F; Christopoulos A
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31878157
[TBL] [Abstract][Full Text] [Related]
26. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
27. Association of polymorphisms of ABCA1 and ROS1 with hypertension in Japanese individuals.
Yamada Y; Kato K; Yoshida T; Yokoi K; Matsuo H; Watanabe S; Ichihara S; Metoki N; Yoshida H; Satoh K; Aoyagi Y; Yasunaga A; Park H; Tanaka M; Nozawa Y
Int J Mol Med; 2008 Jan; 21(1):83-9. PubMed ID: 18097620
[TBL] [Abstract][Full Text] [Related]
28. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
[TBL] [Abstract][Full Text] [Related]
29. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
[TBL] [Abstract][Full Text] [Related]
30. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
31. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
32. IL-10 Promoter -592 Polymorphism may Influence Susceptibility to HIV Infection in South Indian Population.
Harishankar M; Ravikrishnan H; Ravishankar A; Hanna LE; Swaminathan S; Selvaraj P; Bethunaickan R
Curr HIV Res; 2018; 16(1):58-63. PubMed ID: 29468971
[TBL] [Abstract][Full Text] [Related]
33. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
35. Frequent aerogenous spread with decreased E-cadherin expression of ROS1-rearranged lung cancer predicts poor disease-free survival.
Jin Y; Sun PL; Park SY; Kim H; Park E; Kim G; Cho S; Kim K; Lee CT; Chung JH
Lung Cancer; 2015 Sep; 89(3):343-9. PubMed ID: 26149475
[TBL] [Abstract][Full Text] [Related]
36. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Gainor JF; Shaw AT
Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
[TBL] [Abstract][Full Text] [Related]
37. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
[TBL] [Abstract][Full Text] [Related]
38. FoxP3 genetic variants and risk of non-small cell lung cancer in the Chinese Han population.
He YQ; Bo Q; Yong W; Qiu ZX; Li YL; Li WM
Gene; 2013 Dec; 531(2):422-5. PubMed ID: 24035934
[TBL] [Abstract][Full Text] [Related]
39. Association of XPA Polymorphisms Towards Lung Cancer Susceptibility and its Predictive Role in Overall Survival of North Indians.
Lawania S; Singh N; Behera D; Sharma S
Biochem Genet; 2018 Aug; 56(4):375-396. PubMed ID: 29516319
[TBL] [Abstract][Full Text] [Related]
40. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
